Critical Contrast: Emblem (OTCMKTS:EMMBF) vs. Hyperion DeFi (NASDAQ:HYPD)

Emblem (OTCMKTS:EMMBF) and Hyperion DeFi (NASDAQ:HYPD) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, earnings, analyst recommendations, profitability and valuation.

Analyst Ratings

This is a summary of recent recommendations and price targets for Emblem and Hyperion DeFi, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Emblem	0	0	0	0	0.00
Hyperion DeFi	2	0	1	1	2.25

Hyperion DeFi has a consensus price target of $5.88, indicating a potential upside of 50.18%. Given Hyperion DeFi’s stronger consensus rating and higher possible upside, analysts clearly believe Hyperion DeFi is more favorable than Emblem.

Profitability

This table compares Emblem and Hyperion DeFi’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Emblem	N/A	N/A	N/A
Hyperion DeFi	N/A	-129.97%	-92.39%

Insider & Institutional Ownership

25.8% of Hyperion DeFi shares are owned by institutional investors. 10.9% of Hyperion DeFi shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Emblem and Hyperion DeFi”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Emblem	N/A	N/A	N/A	N/A	N/A
Hyperion DeFi	$810,000.00	55.01	-$45.31 million	($11.80)	-0.33

Emblem has higher earnings, but lower revenue than Hyperion DeFi.

Summary

Hyperion DeFi beats Emblem on 7 of the 9 factors compared between the two stocks.

About Emblem

Emblem Corp. produces, distributes, and sells medical cannabis and cannabis derivatives in Canada. The company also operates medical cannabis education centers to provide education services for making informed decisions about medical cannabis treatment options to physicians and patients. In addition, it provides various accessories. Emblem Corp. has a strategic partnership with GreenSpace Brands to develop and commercialize cannabidiol infused health and beauty products. The company is headquartered in Toronto, Canada. As of March 14, 2019, Emblem Corp. operates as a subsidiary of Aleafia Health Inc.

About Hyperion DeFi

Eyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.